Spectranetics Brings Radiation-reducing Products, Physician Training Simulation to New Cardiovascular Horizons 2013

Share Article

Cardiovascular specialists will receive hands-on experience with new products that reduce physicians' exposure to fluroscopic radiation by up to 75% during vascular intervention procedures.

The Quick-Access Needle Holder extends the physican's reach, allowing the hands to be further from radiation.

June 5 through 7, New Cardiovascular Horizons 2013 will convene in New Orleans to educate and train medical professionals on the latest cardiovascular techniques and technology.

The Spectranetics Corporation(NASDAQ: SPNC), headquartered in Colorado Springs, will be present at the symposium to provide hands-on experience with two of their newest products: Quick-Access® Needle Holder and Quick-Cross Capture® Guidewire Retriever. Both have radiation-reducing features to help protect physicians from repeated exposure during vascular intervention procedures.

"Fluoroscopically-guided interventional procedures require complex manipulations that place the physician's hands in close proximity to the scanning plane," said Andrej Schmidt of Park Hospital, Leipzig Germany. "Radiation exposure is cumulative over a lifetime, and the effects are permanent. The Quick- Access Needle holder facilitates the placement of guidewires into the vascular system during interventional procedures while extending the reach of the physician, allowing 23 cm of additional space to allow the hands to be further from radiation."

Retrograde crossing of chronic total occlusions is an innovative and complex technique, and 40% of physicians expect their usage to increase in the next two years (Source: Survey conducted by Spectranetics August 2012. N=142). Retrieving the guidewire is a time-consuming step in this process, and the Quick-Cross Capture Guidewire Retriever is designed to make retrieving the guidewire quick and predictable, with no damage either to the wire or to the vessel.

Additional conference highlights include:

  • Office-based laser symposium for physicians exploring the opportunities and options in introducing a laser program as part of their practices.
  • Dr. Carlos Mena, Medical Director Vascular Medicine at Yale School of Medicine, live video stream of an investigational procedure using laser atherectomy to treat in-stent restenosis as part of the ongoing EXCITE clinical trial.
  • Symposium and panel discussion on Advanced Techniques and Tools for Retrograde Access led by Dr. Craig Walker, co-founder of NCVH and Director of the Cardiovascular Institute of the South in Houma, LA.
  • Training on the world's only computerized simulator for excimer laser atherectomy – from foundational to advanced – including dedicated sessions for Japanese physicians and over 40 fellows from around the world.

According to Donna Ford-Serbu, Senior Vice President, Global Marketing, Strategy and Portfolio, NCVH 2013 is especially notable. "This will be our first conference opportunity for physicians to experience Quick-Access and Quick-Capture products that we acquired and integrated into our portfolio earlier this year. We believe that the combination of radiation reduction features and precision of control result in important tools to support the increasing demand for retrograde procedures."

Spectranetics invites conference attendees to visit the exhibit in booth 102.

About Spectranetics
Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The company’s products are sold in more than 40 countries and are used to access and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads.

The company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee. The company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. In addition, the company markets aspiration and cardiac laser catheters for the treatment of blockages in the heart, and drug delivery catheters for vascular delivery of drugs and diagnostic agents.

The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit http://www.spectranetics.com.

Safe Harbor Statement
This news release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), as amended, and the Private Securities Litigation Reform Act of 1995, and is subject to the safe harbor created by that section. Forward-looking statements contained in this release constitute our expectations or forecasts of future events as of the date this release was issued and are not statements of historical fact. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” “enable,” “potential,” and other words and terms of similar meaning in connection with any discussion of, among other things, clinical trials, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and product development. You are cautioned not to place undue reliance on these forward-looking statements and to note that they speak only as of the date hereof. Factors that could cause actual results to differ materially from those set forth in the forward-looking statements are set forth in the risk factors listed from time to time in our filings with the SEC. Readers are encouraged to review Item 1A. – Risk Factors and all other disclosures appearing in the Spectranetics Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission, for further information on risks and uncertainties that could affect Spectranetics’ business, financial condition and results of operation. We disclaim any intention or obligation to update or revise any financial projections or forward-looking statements due to new information or other events.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karol Norie
Visit website